Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial.
Hyun Sook KimWon-Ho ChoiBo Young KimSung Soo KimSang-Il LeeSang-Hyon KimSung Jae ChoiGeun-Tae KimJin-Wuk HurMyeung-Su LeeYun Sung KimSeung Jae HongPublished in: The Journal of international medical research (2021)
CELBESTA® was not inferior to CELEBREX® with regard to the pain relief efficacy in RA patients, and the tolerability and safety profiles were excellent and at similar levels for both preparations.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- phase iii
- phase ii
- open label
- end stage renal disease
- study protocol
- chronic kidney disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- chronic pain
- rheumatoid arthritis
- cross sectional
- randomized controlled trial
- neuropathic pain
- systemic lupus erythematosus
- high resolution
- patient reported
- clinical evaluation
- ankylosing spondylitis
- molecularly imprinted